Sandbox:khurram: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 8: | Line 8: | ||
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Diseases | ! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Diseases | ||
| colspan="6" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Clinical manifestations''' | | colspan="6" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Clinical manifestations''' | ||
| | |||
| | |||
! colspan="9" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Para-clinical findings | ! colspan="9" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Para-clinical findings | ||
| colspan="1" rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Gold standard''' | | colspan="1" rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Gold standard''' | ||
Line 13: | Line 15: | ||
|- | |- | ||
| colspan="3" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Symptoms''' | | colspan="3" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Symptoms''' | ||
! colspan=" | | | ||
! colspan="2" rowspan="2" |Physical examination | |||
! | |||
| | |||
|- | |- | ||
! | |||
! | |||
| | |||
! colspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Lab Findings | ! colspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Lab Findings | ||
| | | | ||
Line 20: | Line 28: | ||
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Histopathology | ! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Histopathology | ||
|- | |- | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Pain in | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Pain in extremities | ||
! colspan="1" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Chest pain | ! colspan="1" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Chest pain | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Hemoptysis | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Hemoptysis | ||
!Swelling in extremities | |||
! colspan="1" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Tenderness in extremities | |||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Edema in extremities | |||
!Warmth in extremities | |||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Skin necrosis | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Skin necrosis | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Platelet count | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Platelet count | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |PT | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |PT | ||
Line 39: | Line 49: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 58: | Line 70: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 77: | Line 91: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 96: | Line 112: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 115: | Line 133: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 134: | Line 154: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 150: | Line 172: | ||
|- | |- | ||
|Antiphospholipid antibody syndrome | |Antiphospholipid antibody syndrome | ||
| | |||
| | |||
| | | | ||
| | | |
Revision as of 20:10, 20 August 2018
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief:
Differentiating [disease name] from other diseases on the basis of [symptom 1], [symptom 2], and [symptom 3]
On the basis [symptom 1], [symptom 2], and [symptom 3], [disease name] must be differentiated from [disease 1], [disease 2], [disease 3], [disease 4], [disease 5], and [disease 6].
Diseases | Clinical manifestations | Para-clinical findings | Gold standard | Additional findings | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Symptoms | Physical examination | ||||||||||||||||||
Lab Findings | Imaging | Histopathology | |||||||||||||||||
Pain in extremities | Chest pain | Hemoptysis | Swelling in extremities | Tenderness in extremities | Edema in extremities | Warmth in extremities | Skin necrosis | Platelet count | PT | PTT | Peripheral blood smear | Bleeding time | Doppler ultrasound | Chest CT scan | Head CT with contrast | ||||
Antithrombin deficiency | |||||||||||||||||||
Factor V Leiden mutation | |||||||||||||||||||
Protein C deficiency | |||||||||||||||||||
Protein S deficiency | |||||||||||||||||||
Prothrombin gene mutation | |||||||||||||||||||
DIC | Ristocetin cofactor assay | ||||||||||||||||||
Antiphospholipid antibody syndrome |